Charity Calls for Additional Screening to Increase Cancer Survival Rates

Cancer awareness among the general public is essential and a foundation upon which cancer-control plans can be built. Cancer awareness and survival rates can be boosted by understating the existing problems and exploring possible solutions. This is the reason as to why a charity foundation in the UK has called for increased screening for cancer across several regions. The foundation has also retaliated that stalling the numbers being examined has been the main stumbling block in saving the lives of patients with cancer.

Comparative screening of cancer

It has been noted that cancer screening of individuals who see their general practitioners (“GPs”) with symptoms of cancer is the main reason why such countries have better survival rates than the UK. A complete reconstruction of how cancer is treated should therefore be implemented. Currently, for a patient to be screened, it is the doctors who can decide whether or not it is necessary and give consent.

To boost the cancer survival rates, several one-stop shops that operate free of the GP system need to be established to offer more screening opportunities. Primary care and GPs are the main elements of a sound health system, and they should be supported fully rather than being undermined. The GPs should also be empowered to refer suspected patients to secondary care to boost survival rates.

An expert in the Charity Foundation in the UK introduced a good cancer plan in the year 2000 though ten years later, it has not yielded results. If the program had picked on well, cancer survival rates in the UK would be five times better and the best in Europe. The expert added that poor performance in treating cancer has contributed to more cancer deaths in the UK.

According to the Charity Foundation, the continuous comparative deficiency in cancer outcomes was unraveled in the concord-3 studies. From the study, it was revealed that Sweden, Australia, Norway, and Denmark were much better than the UK when it came to survival rates. All the four countries were doing well in trying to contain the six common types of cancer than the UK.

Other factors that hindered the Charity Foundation’s efforts in battling the disease were lack of scanners.

It was noted that the UK was ranked number 35 out of 37 for the numbers of CT scanners available. To make matters worse, it was at rank 31 out of the 36 nations in terms of the MRI scanners available. Due to these factors, the Charity Foundation is creating awareness to help boost the survival rates of cancer patients. This state of affairs shows why the work being done by biomedical companies like Predictive Oncology (NASDAQ: POAI) is so important in getting needed treatment to cancer patients.

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.